STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
Summary
A Sept. 25, 2026 Pharmalot roundup reports that Heidi Overton, President Trump’s nominee to lead the FDA, faced Senate questioning about China, vaccines, and abortion access but offered few personal positions, referring instead to existing agency guidance and approvals. Separately, Novo Nordisk agreed to pay Nanexa up to $1.3 billion to license and develop PharmaShell, a drug-delivery technology intended to provide controlled release and potentially reduce injection frequency for obesity and diabetes medicines. The excerpt does not provide further deal or hearing details.
Watchmen Signals
Biblical Context
No strong biblical connection is identified. The article concerns an FDA nomination, pharmaceutical regulation, and drug-delivery research. These subjects do not themselves establish a specific biblical principle or prophetic fulfillment, and the excerpt does not raise a distinct moral or theological question requiring biblical interpretation.
Comments
No comments yet.
Sign in to join the conversation.
Sign In